Wrocław Medical University

Novel classification of allergic disorders published by the European Academy of Allergy and Clinical Immunology: SIAF

Retrieved on: 
Tuesday, October 10, 2023
Medicine, European Academy of Allergy and Clinical Immunology, EAACI, Research, Health, Classification, Patient, Education, Nanotechnology, Wrocław Medical University, Tissue, Swiss Institute of Allergy and Asthma Research, Skin, Human, Allergy, Infection, Organ dysfunction, Medical device, Vaccine

DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.

Key Points: 
  • The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.
  • The world's key opinion leaders gathered around the initiative of the European Academy of Allergy and Clinical Immunology (EAACI) to present a new classification of allergic disorders based on the mechanisms of diseases.
  • Published online today in Allergy, the position paper reveals the new way allergic diseases are perceived.
  • We expect the new classification to  profoundly change the healthcare professionals' approach to managing allergic diseases since it provides key solutions to a personalised approach.

Novel classification of allergic disorders published by the European Academy of Allergy and Clinical Immunology: SIAF

Retrieved on: 
Tuesday, October 10, 2023
Medicine, European Academy of Allergy and Clinical Immunology, EAACI, Research, Health, Classification, Patient, Education, Nanotechnology, Wrocław Medical University, Tissue, Swiss Institute of Allergy and Asthma Research, Skin, Human, Allergy, Infection, Organ dysfunction, Medical device, Vaccine

DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.

Key Points: 
  • The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.
  • The world's key opinion leaders gathered around the initiative of the European Academy of Allergy and Clinical Immunology (EAACI) to present a new classification of allergic disorders based on the mechanisms of diseases.
  • Published online today in Allergy, the position paper reveals the new way allergic diseases are perceived.
  • We expect the new classification to  profoundly change the healthcare professionals' approach to managing allergic diseases since it provides key solutions to a personalised approach.

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Groundbreaking Study Validates Allergen Exposure Chamber for Assessing Clinical Outcomes of HDM AIT in Allergic Rhinoconjunctivitis Patients'

Retrieved on: 
Sunday, June 11, 2023
AIT, HDM, Huntington Medical Research Institutes, Wrocław Medical University, VAS, Visual analogue scale, Conjunctivitis, Patient, AEC, Immunoglobulin E, Safety, Medical imaging

The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies.

Key Points: 
  • The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies.
  • Fifty patients with HDM-triggered allergic rhinoconjunctivitis were included in the study, with HDM allergy confirmed through various diagnostic tests such as skin prick tests, serum-specific IgE, and basophil activation tests.
  • During the study, patients were assessed in the allergen exposure chamber before commencing AIT and after 12 months of treatment.
  • The chamber provided a controlled environment, allowing patients to be exposed to HDM allergen under stable and well-regulated conditions.

Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis

Retrieved on: 
Friday, November 26, 2021
Health, Hospitals, Other Health, Managed Care, Pharmaceutical, Biotechnology, Policy, BMC, Patient, Iron, Fresenius Medical Care, Australian Longitudinal Study on Women's Health, Heart, World Health Organization, Degenerative disease, CEO, Clay, Anemia, Common, URL, Nephrology, Function, Diagnosis, Awareness, Woman, Health, Wrocław Medical University, Nutritional anemia, Pica, Systematic review, SIX Swiss Exchange, Disease, COVID-19, Conditional sentence, Veni, vidi, vici, PLOS, Twitter, Risk, Dizziness, Heart failure, Adult, ISIN, Vifor Pharma, B, Iron deficiency, LinkedIn, Infection, Immune system, Fatigue, Medical device, Pharmaceutical industry, Dietary supplement, Hospital, Vifor Pharma Group, iron deficiency, VIFOR PHARMA GROUP, IRON DEFICIENCY

Together, we are dedicated to support people at risk of and living with iron deficiency or iron deficiency anemia so they can lead better, healthier lives.

Key Points: 
  • Together, we are dedicated to support people at risk of and living with iron deficiency or iron deficiency anemia so they can lead better, healthier lives.
  • To learn more about the importance of early diagnosis and recognizing symptoms of iron deficiency, visit www.takeironseriously.com/raise-awareness .
  • Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide7, yet despite the serious consequences and high prevalence8, it remains an under-recognized condition.
  • A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases.

Cardiometabolic Health Congress (CMHC) Launches Digital Education Hub Centered on Iron Deficiency in Heart Failure

Retrieved on: 
Monday, October 11, 2021
CMHC, ID, Publication, IV, FAHA, Doctor of Philosophy, FESC, Department, Iron deficiency, Heart failure, Associate, Diagnosis, Wrocław Medical University, FAQ, Research, George Washington University School of Medicine & Health Sciences, News, Iron, FACP, Quality of life, CME, FACC, University Hospital (Newark, New Jersey), Baylor College of Medicine, Awareness, Baylor University, Patient, Anemia, Risk, Student, Comorbidity, Teaching hospital, Bureau of Oceans and International Environmental and Scientific Affairs, Center, Medical device, Pharmaceutical industry

 While discussing the importance of examining the topic of ID in HF, Dr. Gurusher Panjrath remarked “I think for the clinical community it is important to recognize iron deficiency as an entity in heart failure, recognize that it is separate from anemia--there may be overlap among them but it will be a missed opportunity if we only are looking for anemia and not iron deficiency absent of anemia.” 

Key Points: 
  • The Cardiometabolic Health Congress (CMHC) has recently launched a digital education hub focused on iron deficiency (ID) in heart failure (HF).
  • Iron deficiency is a very common comorbidity in patients with heart failure and can lead to a worsening of heart failure symptoms and decreased quality of life regardless of the absence of anemia.
  • The hub has a variety of expert contributors who have shared in-depth commentary on care strategies for iron deficiency in heart failure.
  • Visit the CMHC Iron Deficiency in Heart Failure educational hub now to access the wide array of valuable resources on this crucial topic.

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device

Retrieved on: 
Friday, August 6, 2021
Medical Devices, Health, Surgery, General Health, Cardiology, Biotechnology, HAART, Medical University of Silesia, CEO, Wrocław Medical University, Dissection, Engineering, Technology, Patient, Congenital heart defect, Bicuspid aortic valve, Almost, Aortic insufficiency, Science, PMID, Surgeon, Aortic aneurysm, HJ, Medical school, Instrumentation

Professor Jasinski commented, The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease.

Key Points: 
  • Professor Jasinski commented, The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease.
  • Our experience with the HAART 300 Aortic Annuloplasty Devices in trileaflet aortic valve repair has shown us how the devices simplify aortic valve repair and at the same time provide durable annuloplasty.
  • John Wheeler, President and CEO, concluded by saying, BioStable is very pleased to initiate commercialization of the HAART 200 Aortic Annuloplasty Device alongside the HAART 300 Devices.
  • With the commercial availability of the HAART 200 and HAART 300 Aortic Annuloplasty Devices, BioStable can offer surgeons within the European a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency.